Latest Breaking News On - Stj - Page 14 : vimarsana.com

Ed Chekan, Author at MedCity News

Dr. Gavin Slethaug, Author at MedCity News

Views of Digital Health from the Oregon Trail

Today, many hope artificial intelligence will be the key that unlocks the value of digitization. Perhaps it will, but the claim that better technology will necessarily improve healthcare is no longer credible. Having lived in both analog and digital worlds, who better than us Oregon Trail doctors to help ensure digital health technologies best serve our workforce, patients, and communities?

Dr. Spencer Dorn, Author at MedCity News

Navigating the Challenges of Pediatric Surgery With Robotic-Assisted Procedures

With the many advantages of robotics, it is time for pediatric patients to garner the same attention and technology development that adult patients have benefitted from for decades.

Bridging the Data Divide: Investing in People and Tech to Improve Health Equity

Proper data collection, analysis, and utilization has the potential to address long-standing health disparities and propel our healthcare system forward to serve all communities.

Network With More Than 100 Healthcare VC firms at MedCity INVEST 2024!

The conference is the premier boutique healthcare investment event in the U.S.

AI Biotech Exscientia Fires CEO Hopkins for Relationships With Two Employees

Exscientia’s termination of CEO Andrew Hopkins is for cause and effective immediately. Grounds for termination include misconduct or behavior that brings Hopkins or the company into disrepute, according to his employment agreement.

"The Name May Be 'Neue' but Their Problems are Old": Will Bright Health's Rebrand Save It?

Bright Health Group recently announced that it is adopting NeueHealth as its corporate brand name after it shed its insurance business and is focusing on its value-based consumer care business. But getting rid of the Bright Health name doesn't get rid of its financial problems, experts say.

This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source

Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.